Drug Trial Radar · NCT03488524
Open Label Extension Study of AMX0035 in Patients With ALS
Last checked: Nov 19, 2026Latest source record: Aug 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
90
Actual
Start
Mar 29, 2018
Primary completion
Mar 1, 2021
Study completion Mar 1, 2021
Sponsor
- Lead sponsor
- Amylyx Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Massachusetts General Hospital
- First posted
- Apr 5, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This extension study, in which all participants received active treatment (AMX0035), was designed to assess the longer-term safety and therapeutic potential of AMX0035 for participants who have completed the Main Study (AMX3500, also known as CENTAUR).
Conditions
- Amyotrophic Lateral Sclerosis
- ALS
Interventions
AMX0035Drug
Combination therapy of PB and TURSO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From the Baseline Visit in the OLE study through Week 132 or the Early Discontinuation (Final Safety) Visit for each participant (for up to approximately 132 weeks)
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
Barrow Neurological Institute-Dignity Health, St Joseph's Hospital and Medical Center
Phoenix, Arizona
University of California, Irvine
Orange, California
California Pacific Medical Center
San Francisco, California
University of Florida College of Medicine
Gainesville, Florida
University of South Florida College of Medicine
Tampa, Florida
Emory University Hospital
Atlanta, Georgia
University of Iowa, Carver College of Medicine
Iowa City, Iowa
University of Kentucky Medical Center
Lexington, Kentucky
Ochsner Neuroscience Institute
New Orleans, Louisiana
Johns Hopkins Hospital
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
University of Massachusetts Memorial Medical Center
Worcester, Massachusetts
University of Michigan, Michigan Medicine
Ann Arbor, Michigan
Hennepin County Medical Center
Minneapolis, Minnesota
Washington University Medical Center
St Louis, Missouri
Neurology Associates, PC
Lincoln, Nebraska
Wake Forest School of Medicine
Winston-Salem, North Carolina
The Ohio State University, Wexner Medical Center
Columbus, Ohio
Oregon Health & Science University
Portland, Oregon
The Penn Comprehensive Neuroscience Center
Philadelphia, Pennsylvania
Temple University Hospital
Philadelphia, Pennsylvania
Texas Neurology, PA
Dallas, Texas
University of Texas Health Science Center, San Antonio
San Antonio, Texas
Swedish Neuroscience Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.